Janus Kinases are enzymes found in cells in the immune system that are critical for the cell signaling process. JAK inhibitors block the inflammatory signaling pathways, inhibiting the genes that trigger autoimmune processes.
The FDA has issued Boxed Warnings for one of the marketed JAK inhibitor drugs used in the comparative study.
The public was notified of serious side effects including an increased risk of blood clots in the lungs and death in rheumatoid arthritis patients taking a standard dose of the product.
In addition to JAK inhibition, MYMD-1 has shown efficacy as a selective inhibitor of TNF-α, a driver of chronic inflammation. MYMD-1 has also been shown to be effective in traversing the blood-brain barrier, a differentiator that can increase the drug's benefit to patients.
MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) is a clinical stage pharmaceutical company.
MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-α and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-α blocking drugs, and aging and longevity.
The company's second drug platform, Supera-CBD, is based on a novel (patent pending) synthetic derivative of cannabidiol that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase.
Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins